Search research articles
Contact Us
Filters
Showing results (21-30 of 137) with videos related to
Page
of 14
Sort By:
Cancer Immunology, Immunotherapy : CII
|
January 7, 2021
Genetic determinants of immune-related adverse events in patients with melanoma receiving immune checkpoint inhibitors
Noha Abdel-Wahab, Adi Diab, Robert K Yu, et al.
Thyroid : Official Journal of the American Thyroid Association
|
August 23, 2018
Immune-Related Thyroiditis with Immune Checkpoint Inhibitors
Priyanka C Iyer, Maria E Cabanillas, Steven G Waguespack, et al.
Journal for Immunotherapy of Cancer
|
January 25, 2017
Erratum to: A case report of Grover's disease from immunotherapy-a skin toxicity induced by inhibition of CTLA-4 but not PD-1
Marc Uemura, Faisal Fa'ak, Cara Haymaker, et al.
Cancers
|
April 12, 2022
Utilization of Immunotherapy for the Treatment of Hepatocellular Carcinoma in the Peri-Transplant Setting: Transplant Oncology View
Maen Abdelrahim, Abdullah Esmail, Ashish Saharia, et al.
Journal for Immunotherapy of Cancer
|
September 24, 2016
A case report of Grover's disease from immunotherapy-a skin toxicity induced by inhibition of CTLA-4 but not PD-1
Marc Uemura, Faisal Fa'ak, Cara Haymaker, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 25, 2021
Current strategies for intratumoural immunotherapy - Beyond immune checkpoint inhibition
Jianda Yuan, Anuradha Khilnani, Joshua Brody, et al.
Future Oncology (London, England)
|
July 30, 2020
Bempegaldesleukin plus nivolumab in untreated, unresectable or metastatic melanoma: Phase III PIVOT IO 001 study design
Nikhil I Khushalani, Adi Diab, Paolo A Ascierto, et al.
Journal of the National Cancer Institute
|
November 4, 2020
Patient-Reported Outcomes in Clinical Trials Leading to Cancer Immunotherapy Drug Approvals From 2011 to 2018: A Systematic Review
Houssein Safa, Monica Tamil, Philippe E Spiess, et al.
The American Journal of Dermatopathology
|
January 31, 2017
Lichenoid Dermatologic Toxicity From Immune Checkpoint Blockade Therapy: A Detailed Examination of the Clinicopathologic Features
Michael T Tetzlaff, Priyadharsini Nagarajan, Susan Chon, et al.
International Journal of Dermatology
|
November 21, 2017
Regressed melanocytic nevi secondary to pembrolizumab therapy: an emerging melanocytic dermatologic effect from immune checkpoint antibody blockade
Shakuntala H Mauzo, Michael T Tetzlaff, Kelly Nelson, et al.
Page
of 14
Search research articles
Search
Showing results (21-30 of 137) with videos related to
Sort By:
Page
of 14
Cancer Immunology, Immunotherapy : CII
|
January 7, 2021
Genetic determinants of immune-related adverse events in patients with melanoma receiving immune checkpoint inhibitors
Noha Abdel-Wahab, Adi Diab, Robert K Yu, et al.
Thyroid : Official Journal of the American Thyroid Association
|
August 23, 2018
Immune-Related Thyroiditis with Immune Checkpoint Inhibitors
Priyanka C Iyer, Maria E Cabanillas, Steven G Waguespack, et al.
Journal for Immunotherapy of Cancer
|
January 25, 2017
Erratum to: A case report of Grover's disease from immunotherapy-a skin toxicity induced by inhibition of CTLA-4 but not PD-1
Marc Uemura, Faisal Fa'ak, Cara Haymaker, et al.
Cancers
|
April 12, 2022
Utilization of Immunotherapy for the Treatment of Hepatocellular Carcinoma in the Peri-Transplant Setting: Transplant Oncology View
Maen Abdelrahim, Abdullah Esmail, Ashish Saharia, et al.
Journal for Immunotherapy of Cancer
|
September 24, 2016
A case report of Grover's disease from immunotherapy-a skin toxicity induced by inhibition of CTLA-4 but not PD-1
Marc Uemura, Faisal Fa'ak, Cara Haymaker, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 25, 2021
Current strategies for intratumoural immunotherapy - Beyond immune checkpoint inhibition
Jianda Yuan, Anuradha Khilnani, Joshua Brody, et al.
Future Oncology (London, England)
|
July 30, 2020
Bempegaldesleukin plus nivolumab in untreated, unresectable or metastatic melanoma: Phase III PIVOT IO 001 study design
Nikhil I Khushalani, Adi Diab, Paolo A Ascierto, et al.
Journal of the National Cancer Institute
|
November 4, 2020
Patient-Reported Outcomes in Clinical Trials Leading to Cancer Immunotherapy Drug Approvals From 2011 to 2018: A Systematic Review
Houssein Safa, Monica Tamil, Philippe E Spiess, et al.
The American Journal of Dermatopathology
|
January 31, 2017
Lichenoid Dermatologic Toxicity From Immune Checkpoint Blockade Therapy: A Detailed Examination of the Clinicopathologic Features
Michael T Tetzlaff, Priyadharsini Nagarajan, Susan Chon, et al.
International Journal of Dermatology
|
November 21, 2017
Regressed melanocytic nevi secondary to pembrolizumab therapy: an emerging melanocytic dermatologic effect from immune checkpoint antibody blockade
Shakuntala H Mauzo, Michael T Tetzlaff, Kelly Nelson, et al.
Page
of 14